New drug combo for lung cancer after immunotherapy stops working
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug combination (N-803 and tislelizumab with chemotherapy) for people whose lung cancer stopped responding to standard immunotherapy. The goal is to see if this treatment can help shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer.
- Your cancer got worse after first responding to a combination of chemotherapy with platinum and an immunotherapy drug.
- You have at least one measurable tumor on a scan.
- You are well enough to be up and about (ECOG score 0-2).
- You do not have an active autoimmune disease that requires treatment with steroids or other immune-suppressing medicines.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, tislelizumab and anlotinib, for people with advanced non-small cell lung cancer that has progressed after initial immunotherapy. The goal is to see if this new combination can help control the cancer.
This trial tests a drug called Tislelizumab (an immunotherapy) combined with chemotherapy for people with advanced NSCLC who have already been helped by a different immunotherapy. It's a second-line option for those who did well on their first immunotherapy but now need another treatment.
This study tests a new combination of two drugs—an immunotherapy called tislelizumab and an experimental antibody-drug conjugate called SYS6010—for people with advanced non-small cell lung cancer who have already tried immunotherapy and their cancer continued to grow. The goal is to see if this combination can help control the cancer better.
This trial combines an immunotherapy drug (tislelizumab) with chemotherapy before surgery to try to shrink the tumor and possibly make surgery possible later. The goal is to improve outcomes for people with stage III non-small cell lung cancer that is not removable at diagnosis.
This trial tests a new combination of three drugs for people with advanced non-small cell lung cancer that has grown despite previous immunotherapy. The goal is to see if adding these drugs can help control the cancer better.
This trial tests a combination of tislelizumab (an immunotherapy drug) with chemotherapy for people with a type of lung cancer that has not spread to other organs and cannot be removed with surgery. The goal is to see if this treatment can shrink tumors and help people live longer.
Hear when a new NSCLC Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.